The cobas® EZH2 Mutation Test was used first as an investigational diagnostic device to screen patients for the tazemetostat clinical study to evaluate the treatment of two subtypes of NHL: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.